Months removed from buying its way into the world of Big Data genomics, Chinese CRO WuXi PharmaTech has partnered up with DNAnexus to take its technology to the cloud.
Indian biotech giant Biocon is planning to take Syngene, its in-house CRO, public in an IPO on the local exchange.
Biopharma production specialist Sartorius Stedim Biotech has acquired BioOutsource, a U.K. CRO focused on the growing demand for knockoffs of top-selling biologics.
PPD has opened a new central lab facility in Shanghai, expanding its testing services into China as it stretches out around the globe.
Catalent doubled its capacity at a Kentucky manufacturing facility, wrapping up a $52 million project with plans to add about 140 new workers.
Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.
Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.
Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.
U.S. contractor Aptuit has signed a deal with Italy's Axxam to team up on early-stage R&D services, pooling their resources to better compete for projects.
Serial acquirer Clinipace has bought up European CRO Accovion, striking its 6th deal in as many years as it seeks to expand its global reach.
West Virginia bioanalytics outfit Protea Biosciences has acquired preclinical researcher vivoPharm to expand in the world of early-stage oncology development.
Chinese CRO WuXi PharmaTech has pushed one of its manufacturing subsidiaries onto the local stock market, selling off a stake as it focuses on its high-growth biologics business.
CRO giant Parexel International has unveiled three new education programs in partnership with schools around the world, lending its expertise in hopes of training the next generation of clinical researchers.
Catalent is buying a drug packaging operation in Australia, extending its global reach with a focus on the Asia-Pacific region.
PPD and partner Shin Nippon Biomedical Laboratories have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials.
Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.
Indian conglomerate Piramal has sold off its CRO business to Indoco Remedies, getting rid of a business "not considered strategic in nature," according to the company.
In its first big move since pulling off a $306 million IPO, PRA Health Sciences is stretching out its early-stage development efforts, expanding its Phase I heft around the world.
Partners WuXi PharmaTech and AstraZeneca's MedImmune are on schedule with a rheumatoid arthritis-treating antibody designed for the Chinese market, as the country's regulators have accepted their application.
X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.